We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$328M
AUM Growth
-$55.1M
Cap. Flow
-$44.7M
Cap. Flow %
-13.62%
Top 10 Hldgs %
42.21%
Holding
136
New
34
Increased
27
Reduced
16
Closed
41

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.8M
2
SLNO
Soleno Therapeutics
SLNO
+$14.3M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.24M
4
TGTX icon
TG Therapeutics
TGTX
+$6.09M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$4.61M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
ARGX icon
argenx
ARGX
+$3.66M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.54M
4
LLY icon
Eli Lilly
LLY
+$3.49M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 49.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
26
Vertex Pharmaceuticals
VRTX
$121B
$4.45M 1.36%
+10,000
New +$4.61M
PTGX icon
27
Protagonist Therapeutics
PTGX
$8.79B
$4.21M 1.28%
+76,185
New +$3.66M
AGIO icon
28
CALL
Agios Pharmaceuticals
AGIO
$1.79B
$4.06M 1.24%
122,100
+2,400
+2% +$72.7K
MREO
29
CALL
Mereo BioPharma
MREO
$54.7M
$3.57M 1.09%
1,317,600
+802,400
+156% +$1.94M
RXRX icon
30
CALL
Recursion Pharmaceuticals
RXRX
$1.59B
$3.53M 1.08%
698,400
– –
GILD icon
31
Gilead Sciences
GILD
$162B
$3.33M 1.01%
+30,000
New +$3.19M
ARGX icon
32
argenx
ARGX
$54.6B
$3.29M 1%
5,974
-6,305
-51% -$3.66M
IMCR icon
33
Immunocore
IMCR
$1.72B
$3.28M 1%
104,384
+7,400
+8% +$230K
REGN icon
34
Regeneron Pharmaceuticals
REGN
$78.5B
$2.94M 0.9%
5,607
-24,221
-81% -$13.5M
RVMD icon
35
Revolution Medicines
RVMD
$39.9B
$2.91M 0.89%
+79,079
New +$3.04M
MRNA icon
36
CALL
Moderna
MRNA
$21.8B
$2.82M 0.86%
102,100
+50,000
+96% +$1.32M
COGT icon
37
Cogent Biosciences
COGT
$6.65B
$2.82M 0.86%
392,213
– –
MRNA icon
38
PUT
Moderna
MRNA
$21.8B
$2.76M 0.84%
100,000
– –
ZYME icon
39
CALL
Zymeworks
ZYME
$1.61B
$2.25M 0.69%
179,300
– –
SRRK icon
40
Scholar Rock
SRRK
$5.67B
$2.23M 0.68%
62,926
+5,003
+9% +$157K
ITOS
41
DELISTED
iTeos Therapeutics
ITOS
$2.06M 0.63%
+206,200
New +$1.66M
URGN icon
42
UroGen Pharma
URGN
$1.86B
$2.06M 0.63%
150,000
+73,780
+97% +$708K
RARE icon
43
Ultragenyx Pharmaceutical
RARE
$2.45B
$1.96M 0.6%
+53,985
New +$1.95M
MLTX icon
44
PUT
MoonLake Immunotherapeutics
MLTX
$1.57B
$1.95M 0.59%
+41,300
New +$1.68M
MNKD icon
45
CALL
MannKind Corp
MNKD
$1.21B
$1.94M 0.59%
519,900
– –
ACAD icon
46
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
$1.92M 0.58%
+88,900
New +$1.65M
SCPH
47
CALL
DELISTED
scPharmaceuticals
SCPH
$1.85M 0.56%
+486,500
New +$1.51M
VRDN icon
48
Viridian Therapeutics
VRDN
$2.09B
$1.71M 0.52%
122,061
-40,002
-25% -$543K
SMMT icon
49
CALL
Summit Therapeutics
SMMT
$10.4B
$1.59M 0.48%
74,700
+50,000
+202% +$1.14M
MRK icon
50
Merck
MRK
$322B
$1.58M 0.48%
+20,000
New +$1.59M
1
2
3 4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Diadema Partners held 136 positions worth $328M, down 14% from $383M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Diadema Partners withdrew a net $44.7M in Q2 2025, closing 41 positions and reducing 16 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $3.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 33% a quarter earlier.

Against the trend, Diadema Partners opened a new position in Amgen worth $14.5M.

  • Diadema Partners's largest Q2 2025 buy was Amgen: 52,100 shares worth $14.5M.
  • Diadema Partners added most to Soleno Therapeutics in Q2 2025, an estimated $14.3M increase.
  • Diadema Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Alnylam Pharmaceuticals in Q2 2025, selling an estimated $3.54M.
  • Diadema Partners's ten largest holdings make up 42% of its $328M portfolio in Q2 2025.
  • Diadema Partners opened 34 new positions and closed 41 in Q2 2025.
  • Diadema Partners's portfolio value fell 14% quarter-over-quarter to $328M.

Based on Diadema Partners's 13F filing for Q2 2025, filed 14 Aug 2025.